Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
| dc.rights.license | open | en_US |
| dc.contributor.author | MEYNARD, Lucie | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DINART, Derek | |
| dc.contributor.author | DELAUNAY, Blandine | |
| dc.contributor.author | FLECHON, Aude | |
| dc.contributor.author | SALDANA, Carolina | |
| dc.contributor.author | LEFORT, Felix | |
| dc.contributor.author | GRAVIS, Gwenaelle | |
| dc.contributor.author | THIERY-VUILLEMIN, Antoine | |
| dc.contributor.author | CANCEL, Mathilde | |
| dc.contributor.author | COQUAN, Elodie | |
| dc.contributor.author | LADOIRE, Sylvain | |
| dc.contributor.author | MAILLET, Denis | |
| dc.contributor.author | ROLLAND, Frederic | |
| dc.contributor.author | BOUGHALEM, Elouen | |
| dc.contributor.author | MARTIN, Sophie | |
| dc.contributor.author | LARAMAS, Mathieu | |
| dc.contributor.author | CROUZET, Laurence | |
| dc.contributor.author | ABBAR, Baptiste | |
| dc.contributor.author | FALKOWSKI, Sabrina | |
| dc.contributor.author | POUESSEL, Damien | |
| dc.contributor.author | ROUBAUD, Guilhem | |
| dc.date.accessioned | 2022-11-02T09:28:55Z | |
| dc.date.available | 2022-11-02T09:28:55Z | |
| dc.date.issued | 2022-09-08 | |
| dc.identifier.issn | 1879-0852 (Electronic) 0959-8049 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170186 | |
| dc.description.abstractEn | BACKGROUND: Recent studies suggest improvements in response to salvage chemotherapy (CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was to assess the efficacy of chemotherapy re-challenge after ICI, compared with second-line chemotherapy without previous ICI in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). METHODS: In this multicentre retrospective study, we included all patients with la/mUC initiating second or third-line chemotherapy from January 2015 to June 2020. We compared patients treated with second-line chemotherapy without previous ICI (CT2) and patients treated with third-line chemotherapy after ICI (CT3). The primary end-point was objective response rate (ORR) in CT3 compared with CT2. Secondary end-points included progression-free survival (PFS) and toxicities. RESULTS: Overall, 553 patients were included. ORRs were 31.0% (95% CI, 26.5 to 35.5) and 29.2% (95% CI, 21.9 to 36.6), respectively, in CT2 and CT3, with no statistically significant differences (P = 0.62). In subgroup analyses, no differences in ORR were observed by Bellmunt risk group, type of chemotherapy (platinum or taxanes), duration of response to first-platinum-based chemotherapy (< or ≥ 12 months) or FGFR-status. Median PFS was 4.6 months (95% CI, 3.9 to 5.1) and 4.9 months (95% CI, 4.1 to 5.5) in CT2 and CT3, respectively, and grade 3-4 hematologic toxicity occurred in 35.0% and 22.4% of patients. CONCLUSION: This large multicentre retrospective study provides clinically relevant real-world data. Chemotherapy re-challenge after ICI in la/mUC achieves ORR and PFS comparable with those obtained in CT2 with an acceptable safety profile. These updated results offer more promising outcomes than historically reported with second-line chemotherapy data. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Urothelial carcinoma | |
| dc.subject.en | Immune checkpoint inhibitor | |
| dc.subject.en | Chemotherapy | |
| dc.title.en | Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.ejca.2022.08.014 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 36088671 | en_US |
| bordeaux.journal | European Journal of Cancer | en_US |
| bordeaux.page | 43-53 | en_US |
| bordeaux.volume | 175 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03836416 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-11-02T09:29:04Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Cancer&rft.date=2022-09-08&rft.volume=175&rft.spage=43-53&rft.epage=43-53&rft.eissn=1879-0852%20(Electronic)%200959-8049%20(Linking)&rft.issn=1879-0852%20(Electronic)%200959-8049%20(Linking)&rft.au=MEYNARD,%20Lucie&DINART,%20Derek&DELAUNAY,%20Blandine&FLECHON,%20Aude&SALDANA,%20Carolina&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||